Inoue, H., Morino, K., Ugi, S., Tanaka‐Mizuno, S., Fuse, K., Miyazawa, I., . . . group, t. S. R. (2019). Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. Wiley.
Chicago Style (17th ed.) CitationInoue, Hideka, et al. Ipragliflozin, a Sodium–glucose Cotransporter 2 Inhibitor, Reduces Bodyweight and Fat Mass, but Not Muscle Mass, in Japanese Type 2 Diabetes Patients Treated with Insulin: A Randomized Clinical Trial. Wiley, 2019.
MLA (8th ed.) CitationInoue, Hideka, et al. Ipragliflozin, a Sodium–glucose Cotransporter 2 Inhibitor, Reduces Bodyweight and Fat Mass, but Not Muscle Mass, in Japanese Type 2 Diabetes Patients Treated with Insulin: A Randomized Clinical Trial. Wiley, 2019.